Compare TLX & BXMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | BXMT |
|---|---|---|
| Founded | 2015 | 1966 |
| Country | Australia | United States |
| Employees | 1184 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | N/A | 1998 |
| Metric | TLX | BXMT |
|---|---|---|
| Price | $11.54 | $17.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.13 | ★ $21.38 |
| AVG Volume (30 Days) | 208.5K | ★ 1.6M |
| Earning Date | 08-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | N/A | ★ 154.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $150.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $16.88 |
| 52 Week High | $16.85 | $20.67 |
| Indicator | TLX | BXMT |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 37.50 |
| Support Level | $9.46 | $16.88 |
| Resistance Level | N/A | $18.84 |
| Average True Range (ATR) | 0.29 | 0.38 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 72.53 | 8.89 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.